Ulisse Biomed S.p.A. (BIT:HLX)
Italy flag Italy · Delayed Price · Currency is EUR
0.8080
+0.0020 (0.25%)
At close: Dec 15, 2025

Ulisse Biomed Company Description

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.

The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples.

It provides various tests and reagents for sexually transmitted diseases and HPV. In addition, the company’s platforms also comprise NanoHybrid, a platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens.

Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.

Ulisse Biomed S.p.A.
CountryItaly
Founded2015
IndustryBiological Products, Except Diagnostic Substances
Employees22
CEONicola Basile

Contact Details

Address:
Via Cavour, 20
Udine, 33100
Italy
Phone39 04 03 75 75 40
Websiteulissebiomed.com

Stock Details

Ticker SymbolHLX
ExchangeBorsa Italiana
Fiscal YearJanuary - December
Reporting CurrencyEUR
SIC Code2836

Key Executives

NamePosition
Nicola BasileChief Executive Officer
Nicola BasileChief Financial Officer
Bruna MariniChief Operating Officer
Gabriele SalarisHead of Investor Relations